DR. REDDY S LABORATORIES (DRREDDY)
companyActive threads
Dr Reddy's faces Q1 earnings squeeze
Dr Reddy’s Laboratories (DRL) is expected to face considerable earnings pressure in the first quarter of the current fiscal ended June 30, 2026. The company will announce its first quarter numbers on July 22, 2026.
Dr Reddys Share Price Live Updates: Dr. Reddys Market Performance - The Economic Times
Dr Reddys Share Price Live Updates: Dr. Reddys Market Performance 06 Nov 2026 | 10:01:51 AM IST Dr Reddys share price live updates Welcome to the Dr Reddys Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent stocks in the market.
Dr Reddy's Laboratories gets Brazil regulator approval for generic semaglutide - CNBC TV18
Dr Reddy's Laboratories gets Brazil regulator approval for generic semaglutide - Published OnNov 5, 2026 | 10:43 IST - Last Updated OnNov 5, 2026 | 10:43 IST The semaglutide injection is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise, either as monotherapy when metformin is considered appropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.
JPMorgan upgrades Dr. Reddy's after Q2, shares rise 5%
JPMorgan upgraded Dr. Reddy's following its Q2 results but remains on the sidelines, citing lingering concerns. Despite the cautious stance, the stock rose 5% as investors reacted positively to the upgrade and quarterly performance.
Dr Reddy's Q2 profit falls 36% to ₹925 crore as Revlimid sales weaken
Dr Reddy's reported a 36% year-on-year drop in Q2 profit to ₹925 crore, driven by weakening Revlimid sales, while management called the cap on trade margins a positive. The company is pivoting to new launches, including a November relaunch of semaglutide and the introduction of Obeda Pro and Obeda Plus amid supply disruptions.
Intelligence feed· 1 article in 1440m
Dr Reddys Share Price Live Updates: Dr. Reddys Market Performance - The Economic Times
Story first reported.